selected scholarly activity
-
conferences
- Determinants of Masked Hypertension in Hypertensive Patients Treated in the Real-Life Observational DioVantageIV Study. Circulation. S474-S475. 2009
- Results from the Canadian valsartan observational hypertension study (Diovantage 4). Canadian Journal of Cardiology. 118C-118C. 2007
-
journal articles
- Development and validation of a decision aid for choosing among antithrombotic agents for atrial fibrillation. Thrombosis Research. 145:143-148. 2016
- Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation.. Journal of Population Therapeutics and Clinical Pharmacology. 20:e229-e237. 2013
- Determinants of masked hypertension in hypertensive patients treated in a primary care setting. Internal Medicine Journal. 42:260-266. 2012
- Shared Electronic Vascular Risk Decision Support in Primary Care. JAMA Internal Medicine. 171:1736-1736. 2011
- Reaching the therapeutic goal in hypertension: results from the Canadian valsartan observational study. (Diovantage 4).. Journal of Population Therapeutics and Clinical Pharmacology. 15:e177-e187. 2008
- AVAPROMISE: A randomized clinical trial for increasing adherence through behavioural modification in essential hypertension.. Cardiology (Pakistan). 7:165-172. 2002
- Atrial fibrillation update. Mature Medicine Canada. 3:14-17. 2000
- Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. The Lancet. 355:253-259. 2000
- Lowering blood pressure the natural way. Mature Medicine Canada. 2:275-278. 1999
- Smoking cessation. Mature Medicine Canada. 2:248-250. 1999
- Hypertension update. Mature Medicine Canada. 2:118-122. 1999
- Cardiovascular drugs to the year 2000. Mature Medicine Canada. 2:189-193. 1999
- The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.. Canadian Journal of Cardiology. 12:127-137. 1996
- Collaborative cardiovascular clinical trials in Canada. The Canadian Cardiovascular Collaboration.. Canadian Journal of Cardiology. 11:649-657. 1995
- Fenofibrate: A third-generation fibrate lipid-regulating agent. Today's Therapeutic Trends. 12:93-101. 1994
- Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia.. Canadian Journal of Cardiology. 9:405-412. 1993
- Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia.. Clinical Therapeutics. 14:276-291. 1992